Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

~4 mi. (Worms, Germany, +94 more cities)

Klinikum Worms

HER2 Negative

Breast Carcinoma

sacituzumab govitecan

chemotherapy, +1 more type

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

~11 mi. (Mannheim, Germany, +201 more cities)

Universitatsklinikum Mannheim /ID# 221172

Myelodysplastic Syndromes

azacitidine, +1 more drug

chemotherapy

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

~11 mi. (Mannheim, Germany, +197 more cities)

Universitatsklinikum Mannheim /ID# 239762

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

~11 mi. (Mannheim, Germany, +189 more cities)

Universitatsklinikum Mannheim /ID# 221529

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

navitoclax, +1 more drug

targeted therapy

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

~11 mi. (Mannheim, Germany, +32 more cities)

Novartis Investigative Site

BCR-ABL1 Fusion, +1 more biomarker

Chronic Myeloid Leukemia

asciminib

targeted therapy

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

~11 mi. (Mannheim, Germany, +165 more cities)

Universitatsklinikum Mannheim /ID# 221523

del(11)(q10), +27 more biomarkers

Myelofibrosis

navitoclax, +1 more drug

targeted therapy

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

~11 mi. (Mannheim, Germany, +228 more cities)

Universitatsklinikum Mannheim /ID# 228798

MET Expression

Non-Small Cell Lung Carcinoma

telisotuzumab vedotin

chemotherapy, +1 more type

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

~11 mi. (Mannheim, Germany, +8 more cities)

Novartis Investigative Site

Chronic Myeloid Leukemia

asciminib

targeted therapy

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

~11 mi. (Mannheim, Germany, +31 more cities)

Novartis Investigative Site

Myelofibrosis

crizanlizumab, +5 more drugs

immunotherapy, +2 more types

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

~26 mi. (Heidelberg, Germany, +172 more cities)

Thoraxklinik-Heidelberg gGmbH

RET Fusion

Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~26 mi. (Heidelberg, Germany, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

~26 mi. (Heidelberg, Germany, +145 more cities)

Universitaetsklinikum Heidelberg. ( Site 1204)

Non-Small Cell Lung Carcinoma

pembrolizumab, +1 more drug

immunotherapy, +2 more types